Related Experiment Video

Updated: Jul 10, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Fatty acid synthase inhibitors: new directions for oncology

Steven J Kridel1, W Todd Lowther, Charles W Pemble

  • 1Wake Forest University School of Medicine, Department of Cancer Biology, Medical Center Boulevard, Winston-Salem, North Carolina 27157, USA. skridel@wfubmc.edu

Expert Opinion on Investigational Drugs
|November 1, 2007
PubMed

Insights

Fatty acid synthase (FASN) inhibitors show promise as anticancer agents by blocking fatty acid synthesis. This review details their preclinical development and antitumor effects.

Area of Science:

  • Biochemistry
  • Oncology
  • Drug Discovery

Background:

  • Fatty acid synthase (FASN) is crucial for de novo fatty acid synthesis.
  • Overexpressed FASN in various cancers makes it a viable therapeutic target.
  • Pharmacologic FASN inhibitors offer potential anticancer strategies.

Purpose of the Study:

  • To review the preclinical development of FASN inhibitors.
  • To discuss their antitumor effects.
  • To outline strategies for novel FASN inhibitor development.

Main Methods:

  • Review of preclinical data on FASN inhibitors.
  • Analysis of antitumor effects in preclinical models.
  • Examination of structural biology advances for inhibitor design.

Main Results:

  • FASN inhibitors demonstrate significant preclinical anticancer activity.
  • Understanding FASN's role in tumor metabolism is enhanced by these inhibitors.
  • Advances in FASN structural biology facilitate novel inhibitor design.

Conclusions:

  • FASN inhibitors represent a promising class of anticancer therapeutics.
  • Continued research into FASN inhibitors is warranted.
  • Novel inhibitor development is actively progressing.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...